



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : C12N 5/00, 5/06, 5/08 C12N 5/22, C07K 15/04	A1	(11) International Publication Number: WO 90/06994 (43) International Publication Date: 28 June 1990 (28.06.90)
---	----	--

(21) International Application Number: PCT/US89/05885

(22) International Filing Date: 15 December 1989 (15.12.89)

(30) Priority data:

286,680	19 December 1988 (19.12.88)	US
340,939	20 April 1989 (20.04.89)	US

(71) Applicant: NEW YORK UNIVERSITY [US/US]; 70 Washington Square South, New York, NY 10012 (US).

(72) Inventors: DALLA-FAVERA, Riccardo ; 3 Washington Square Village, New York, NY 10012 (US). SEREMITIS, Stephanie ; 74 Fifth Avenue, New York, NY 10011 (US).

(74) Agents: FRANKFORT, Howard, M. et al.; Darby & Darby, 805 Third Avenue, New York, NY 10022 (US).

(81) Designated States: AT (European patent), BE (European patent), CH (European patent), DE (European patent), ES (European patent), FR (European patent), GB (European patent), IT (European patent), JP, LU (European patent), NL (European patent), SE (European patent).


Published

*With international search report.
Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.*

(54) Title: METHOD FOR TRANSFORMING HUMAN B LYMPHOCYTES

(57) Abstract

Disclosed herein is a method for transforming human B-cells preferably by infecting them with Epstein-Barr virus followed by transforming the Epstein-Barr virus infected cells with an activated human ras gene. The transformed cells are useful for producing human monoclonal antibodies either without further manipulation or after fusion with antibody-secreting cells.



FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MG	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MR	Mauritania
BE	Belgium	GA	Gabon	MW	Malawi
BF	Burkina Faso	GB	United Kingdom	NL	Netherlands
BG	Bulgaria	HU	Hungary	NO	Norway
BJ	Benin	IT	Italy	RO	Romania
BR	Brazil	JP	Japan	SD	Sudan
CA	Canada	KP	Democratic People's Republic of Korea	SE	Sweden
CF	Central African Republic	KR	Republic of Korea	SN	Senegal
CG	Congo	LI	Liechtenstein	SU	Soviet Union
CH	Switzerland	LK	Sri Lanka	TD	Chad
CM	Cameroon	LU	Luxembourg	TG	Togo
DE	Germany, Federal Republic of	MC	Monaco	US	United States of America
DK	Denmark				

5

10 METHOD FOR TRANSFORMING HUMAN B LYMPHOCYTES
 FIELD OF THE INVENTION

 This invention relates to a method for the production
of transformed human cells that produce, or can be used to
produce, human monoclonal antibodies and can also be employed
15 to transform any mammalian cell.

BACKGROUND OF THE INVENTION

 Since its introduction in 1975, the well-known Kohler
and Milstein technique (Nature 256:495, 1975) for the produc-
20 tion of mouse hybridoma cells has made it possible to produce
large quantities of mouse antigen-specific monoclonal an-
tibodies that are useful in a number of investigative, diagnos-
tic and therapeutic applications. The mouse hybridoma cells,
which are initially produced by the fusion of antibody-produc-
25 ing cells (B-lymphocyte cells, hereinafter referred to as B-
cells) with malignant, transformed B-cells (in vivo trans-
formed, myeloma cells from mice afflicted with myeloma or
plasmacytoma) are capable of producing large quantities of
monoclonal antibodies with predetermined specificities.

30 Using the Kohler and Milstein technique, a B-cell and
a plasmacytoma cell are fused using, for instance, polyethylene
glycol, lysolecithin or Sendai virus as the cell-fusing agents.
A selectable marker must be present in the fused cells to
enable them to be selected from parent cells and other non-
35 hybridoma cells. As an example, the plasmacytoma fusion

necessary for growth of the fused cell in certain media (hypoxanthine-, aminoprotein-, and thymidine- containing medium or HAT medium). This enzyme deficiency enables the resultant hybrids to be selected for their ability to grow in such media.

- 5 This insures that only B-cell:plasmacytoma cell hybrids are recovered since neither parental cells (nor hybrids comprising B-cell: B-cell and plasmacytoma: plasmacytoma cell) can survive in selective media.

- Murine antibodies produced with the Kohler and
- 10 Milstein technique are generally unsuitable for administration to human subjects as in-vivo therapeutic agents, e.g., to provide passive immunity to an infectious agent. The extension of the Kohler and Milstein hybridoma technology to the production of human monoclonal antibodies has been limited,
- 15 largely due to: (1) the lack of good human plasmacytoma cells for use as fusion partners; (2) the low frequency of cell fusion events ("fusion efficiency"); and (3) the relative scarcity of B-cells circulating in human blood and producing specific antibodies against antigens of interest (and the
- 20 inherent difficulties in isolating such cells). These factors make it difficult to obtain hybridoma cell lines secreting human monoclonal antibodies of a predetermined specificity.

- Casali et al. (Science 234:476-479, 1986) disclosed a method which represents some progress toward making human
- 25 monoclonal antibody-producing cells. Normal B-cells obtained from peripheral human blood were pre-selected for their specificity to a given antigen using Fluorescence-Activated Cell Sorting (FACS). Positively selected clones were then established as lymphoblastoid cells in vitro by infecting such
- 30 cells with Epstein-Barr virus (EBV). The EBV infected cells produced antigen-specific human monoclonal antibodies. However, the method of Casali et al. has several significant drawbacks which impair its usefulness: (1) the amount of monoclonal antibodies produced by the Casali et al. cells is
- 35 relatively low, and (2) the antibody producing cells are relatively unstable and some clones stop antibody production prematurely. In addition maintenance of the antigen-specific

antibody production requires repeated cloning of the cells, a time-consuming and inefficient procedure given the low clonogenic (i.e. growth) properties of the resultant lymphoblastoid or lymphoblastoid cell lines (LCL); (3) large-scale production and purification of the monoclonal antibodies is inefficient in view of the long doubling time and high serum requirements of the LCL; and (4) the LCL produced by this process cannot be grown as tumors in animals. Such tumor cell growth permits the amplification and purification of antibodies from ascitic fluids, an efficient method for large scale antibody production that is widely used in making murine monoclonal antibodies. Finally, the Casali et al. method does not dispense with the requirement for identifying a human B-cell specific to a certain antigen.

Copending U.S. patent application Serial No. 041,803 filed April 23, 1987 of Riccardo Dalla-Favera discloses a method for the production of human monoclonal antibody-producing cells. Specific B lymphocytes are selected using the method of Casali et al. (supra), infected with Epstein Barr virus (EBV) and transfected with activated c-myc DNA sequences. The resultant cells are tumorigenic (i.e. can grow in semi-solid medium and animals such as rats or mice) and clonogenic and produce monoclonal antibodies of a predetermined specificity. However, it was found that these cells still produce relatively low amounts of antibody because the transfected lymphoblastoid cells had not undergone differentiation.

Currently there is no convenient and reliable system available for the production of human monoclonal antibodies wherein the monoclonal antibody-producing cells are stable, highly malignant and which can be readily manipulated to produce high antibody titers.

It, is therefore an object of the present invention to provide a method for the production of tumorigenic human cells that are capable of producing human monoclonal antibodies.

A further object of the present invention is to provide a transformed lymphoblastoid cell that is useful as a

fusion partner in the production of human monoclonal antibodies.

Another object of the present invention is to provide a transformed lymphoblastoid cell that demonstrates high level
5 proliferative, differentiation and antibody production properties.

Another object of the present invention is to produce a new human cell line comprising human B-cells infected with Epstein-Barr virus and which have at least one exogenous
10 activated K-, N- or H-ras oncogene DNA sequences.

SUMMARY OF THE INVENTION

The present invention provides a method and a cell line for producing human monoclonal antibodies. According to
15 one embodiment, human B-cells that produce an antibody directed against a specific antigen may be isolated. The isolated human B-cells are immortalized and transformed (transformation is the process of introducing DNA into cells) with an activated oncogene (preferably using an appropriate vector). The immortal-
20 ized human B-cells comprise malignant transformants which undergo terminal differentiation into plasma cells. These clonogenic, tumorigenic cells are effective for producing large amounts of human monoclonal antibodies.

In one particular aspect, the present invention
25 provides a method for preparing human monoclonal antibody producing cells that can grow in culture comprising the steps of infecting human B-cells producing antibodies of a desired specificity with Epstein-Barr virus, and transforming said Epstein-Barr virus infected human B-cells with a vector
30 containing an activated ras gene.

In another embodiment, the present invention provides a method for obtaining transformed human B-cells comprising the steps of infecting human B-lymphocytes with Epstein-Barr Virus, recovering the Epstein-Barr virus-infected human B-lymphocytes,
35 transforming the virus-infected B-lymphocytes with an activated ras vector, and recovering the transformed human B-lymphocytes. The thus transformed cells can be used as fusion partners in

cell-fusions with untransformed human B-cells that have been sensitized with an antigen to produce an antibody with the desired specificity.

In a further aspect, the present invention provides a transformed human cell comprising a human B-lymphocyte infected with Epstein Barr virus, said cell containing DNA segments coding for a selectable genetic marker, and an activated ras gene in the proper orientation and correct reading frame.

These and other aspects of the present invention will be apparent to those of ordinary skill in the art in light of the present description, accompanying claims and appended drawings.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 is a Northern Blot analysis of ras production by cells infected with the retroviral vectors of the present invention and also contains schematic representations of the probes used in said Blot.

Figure 2 is a graph showing the kinetics of antibody production of a B-cell transformed by the method of the present invention.

Figure 3 is a series of graphs showing the increased expression of plasma cell specific antigens in cells transformed according to the method of the present invention.

Figure 4 is an autoradiograph showing thymidine incorporation in cells expressing ras oncogenes.

DETAILED DESCRIPTION OF THE INVENTION

All literature and patent applications cited in the specification are hereby incorporated by reference in their entirety.

This invention involves a method for producing transformed human cells. The method is particularly useful for transforming normal human B-cells into malignant, transformed, differentiated, monoclonal antibody-producing cells. This is important and unexpected as heretofore it was not believed to be possible to make viable, human, transformed, fully differen-

tiated B-cells using in vitro manipulations.

Whereas conventional hybridoma cells are the product of a fusion event using a transformed lymphoblastoid cell and a normal B-cell, the method of the present invention, in one aspect, requires only genetic manipulation of a normal human B-cell. Using the method of the invention, transformed human B-cells, capable of producing human monoclonal antibodies of any desired specificity, can be readily and easily obtained.

In one aspect, the method of the present invention involves selecting a human B-cell producing antibodies to a specific antigen which may be predetermined. The selected B-cells are then infected with Epstein-Barr virus (EBV). The EBV-infected B-cells are then treated so that they take up and express an activated ras oncogene (e.g. H-, N- or K- ras oncogenes). The result is a relatively high incidence of cells producing specific monoclonal antibodies and capable of being grown in vitro in semi-solid media or in vivo in animals.

Thus, the process described above is used to produce human transformed B-cells secreting antibody of predetermined antigenic specificity.

In an alternative embodiment, B-cells are isolated from a patient known to produce antibodies directed against a specific antigen. The B-cells are immortalized with EBV and transformed in bulk with an activated ras gene. Specific immortalized, ras transformed monoclonal antibody producing cells are then identified and isolated using the method of Casali et al., supra.

Using either of the above embodiments, the frequency of obtaining the desired EBV-infected, ras transformed LCL is greatly increased over that obtainable by cell fusion using the traditional Kohler and Milstein (supra) technique. The efficiency of transformation using the method of the present invention is approximately 1×10^{-1} to 1×10^{-2} (i.e., 1-10%), whereas the efficiency of the Kohler and Milstein technique is approximately 1×10^{-6} (i.e. 0.0001%). Thus, the method of the present invention provides an improvement in efficiency comprising several orders of magnitude.

In another embodiment the infection-transformation process described above can be applied to human B-cells which had not been pre-selected for the production of specific antibodies (but which nonetheless have the requisite biochemical machinery in place and produce and secrete antibodies). After infection and ras transformation, such B-cells will possess all of the properties of transformed B-cells, i.e. the ability to over-express ras (or the mutations discussed below), the ability to grow in semi-solid media and in animals as well as the ability to secrete antibody. However, such infected/transformed B-cells can be used as fusion partners together with specific antibody-secreting B-cells to produce hybridomas using more conventional techniques (such as the well-known Kohler and Milstein technique cited above or other hybridoma technology). Such a cell line, designated CB 33 ras II, has been deposited with the American Type Culture Collection (ATCC, Rockville, MD) under Accession No. ATCC CRL 10011.

However, for use as a fusion partner, the immortalized, ras transformed B-cell is preferably first selected for an enzyme deficiency (using techniques well-known in the art) such as the HGPRT mentioned above. As in the above-mentioned mouse plasmacytoma cell used in the Kohler and Milstein technique, this allows for the selection of monoclonal antibody producing hybridomas by their ability to grow in HAT medium.

Specific monoclonal antibodies produced by the hybridomas of the present invention can be recovered from the supernatants of antibody-producing cells and purified using techniques well-known in the art such as ammonium sulfate precipitation, Protein-A Sepharose chromatography, High Performance Liquid Chromatography (HPLC), and/or combinations thereof.

EBV-infected B-cells demonstrate properties which are intermediate between normal human cells and malignant tumorigenic human cells. The EBV infected B-cells (LCL) exhibit the ability to grow in tissue culture indefinitely in the presence of serum-containing medium. However, they lack the ability to produce colonies when grown in semi-solid medium

(agar) and are unable to grow when injected into susceptible hosts, such as mice or rats. Therefore, the method of the present invention comprises transforming immortalized (e.g. EBV-infected) human B-cells with a vector which confers upon
5 the recipient cells the ability to differentiate (i.e. to acquire the properties of differentiated B-cells) and preferably also one or more of the following properties: (a) the ability to grow in semi-solid media, or animals and (b) the ability to express high levels of certain gene products. A
10 vector that contains an activated ras gene is capable of conferring all of these properties to the target cell (hereinafter an "activated ras vector").

The conversion of normal mammalian cells to the transformed state is usually associated with the activation of
15 one or more oncogenes. For example, the H- ras gene is that portion of the genome of the Harvey Sarcoma Virus that is responsible for the ability of the virus to induce a variety of tumors within weeks after injection of the virus into newly hatched chicks. Thus, a cell can become transformed by a virus.
20 by acquiring the viral oncogene, such as K-ras. A cell can also be transformed through overexpression of an apparently normal gene such as N-ras, resulting in higher observed concentrations of the expression products of the gene (and any genes that are co-expressed with the normal gene) or through
25 mutation (see below). The ras gene has been found to be activated in some cases of multiple myeloma and in many other human malignancies. Ras genes have been identified in mammals, birds, insects, mollusks, plants, fungi and yeasts.

Ras genes, independent of their species of origin,
30 code for proteins that are associated with the plasma membrane, bind guanine nucleotides, and have GTPase (guanosine triphosphatase) activity. It is believed that ras proteins may participate in the transduction of signals across cellular membranes. Although an activated ras gene is preferred for use
35 in the present invention, any activated oncogene (or other gene) which can cause immortalized B-cells to differentiate into mature plasma cells may be employed.

In other words, a gene that causes the immortalized B-cells to differentiate into mature plasma cells (while preserving their ability - if such B-cells already process such ability - to secrete antibody) would be useful in the process of the present invention. Naturally, a gene (as in the case of the ras oncogene) that also confers on the transformed antibody-secreting cell (or to a hybridoma made with a cell that has been transformed in accordance with the present invention) at least one of the following properties is preferred: (1) the ability to grow in animals, (2) the ability to grow in semi-solid media and/or (3) the ability to express large quantities of antibody.

The EBV-infected/ras-transformed cells of the present invention produce monoclonal antibodies, display a relatively short doubling time (on the order of about 36 hours), are clonogenic in semi-solid media and are tumorigenic in experimental animals. In vitro transformation (i.e. generation of clonogenic and tumorigenic cells) of human B-lymphocytes by an activated ras gene has not been previously carried out.

Normal human B-cells for use in the present invention can be isolated from peripheral human blood using conventional methods that are well known to those in the art. The isolated B-cells can be selected for their ability to produce antibodies directed against any antigen using the method of Casali et al., supra as described in Example 5 below (or not so selected - as will be described below by reference to an alternative embodiment). Once human B-cells that produce antibodies directed against a specific antigen have been isolated, they are infected with EBV (obtained by culturing EBV-infected marmoset leukocyte cell line B95-8, available from the American Type Culture Collection (ATCC Rockville, MD) as ATCC CRL 1612), according to well-known methods as illustrated in Example 2 below. The amount of EBV needed for infection is the quantity that will result in a successful infection or, about one transforming unit per cell as described below.

In a particularly preferred embodiment, prior to EBV infection the specific antibody-producing human B-cells (that

have been obtained from the peripheral blood) are screened. The mature B-cells that produce IgG are identified and segregated. The IgG producing B-cells yield antibodies having a higher affinity for specific antigens. The isolated IgG
5 producing B-cells are preferred for use in practicing the method of the invention.

Most EBV-infected B-cells that have been studied, have been found to produce IgM. However, IgG producing B-cells can be easily selected because they display differentiation-
10 associated surface markers such as PCA-1, B-1 (commercially available antibodies to these markers can be obtained from Coulter Immunology, Hialeah, Florida) and OKT10 (commercially available antibodies to OKT10 can be obtained from Ortho Diagnostics) which can be selectively identified as shown in
15 Example 4 below.

After the B-cells have been immortalized, an effective amount of an activated ras gene is introduced into these LCL as discussed below. An effective amount of an activated ras gene is the quantity or titer that accomplishes
20 at least the first of the following three goals (a) differentiation of the B-cells; (b) transformation of the B-cells into the "malignant" phenotype; and (c) production by the B-cell of high levels of ras expression products (and products of co-expressed genes). An activated ras gene is defined as a ras
25 gene (e.g. H-, N- or K-ras) which expresses a mutated gene product or a constitutive (i.e., not regulated) high level of the normal (non-mutated) ras protein. High levels of the normal protein or certain mutations in the coding region (see below) of this protein have been found to induce unrestrained
30 cell division in human cells. For purposes of the invention the ras gene may be "activated" by:

- (1) mutation of "restraining" sequences present in the gene; or
 - (2) insertion of "enhancer" elements adjacent to
35 said gene; or
 - (3) by a combination of these two procedures.
- Any technique for introducing DNA into eukaryotic

cells can be used for transformation of the vector materials into mammalian cells. Well-known techniques for introducing DNA into mammalian cells which can be used in practicing the present invention include, but are not limited to, retroviral
5 vectors, microinjection, calcium phosphate precipitation, DEAE-dextran protoplast fusion or electroporation. Retroviral vectors are preferred because of the high efficiency (approaching 10%) of gene transfer. Other techniques may be more efficient when using different cell types as is well known in
10 the art. The most efficient technique for use with a given cell type can be determined by routine experimentation.

Microinjection involves the direct injection of vectors into the nucleus of eukaryotic cells (as described in Capecchi, M.R., Cell 22:479-488, 1980). A drawback of this
15 technique is that it requires sophisticated machinery for the delivery of very small volumes (nanoliters) and an operator with considerable technical expertise.

DEAE-dextran-mediated protoplast fusion employs a fusion event between the recipient cell and a bacterium
20 carrying the vector of interest (Sandri-Goldin, R.M. et al Mol. Cell Biol. 1:743-752, 1981).

Calcium-phosphate precipitation induces uptake of DNA (or vector) into cells (Graham, F.L. et al, Virology 52:456-467, 1973) The vector is then translocated into the nucleus of
25 these cells.

Electroporation involves exposing a cell suspension to a brief electrical impulse which results in the transfer of DNA into cells (Potter, H.L. et al., Proc. Nat. Acad. Sci., USA 81:7161-7165, 1984). DNA entry is believed to occur via local
30 areas of reversible membrane breakdown (or pores) created by the external electrical field.

The activated ras vectors used in the Examples presented below, termed SVNras and raszip6, are produced by standard cloning techniques, well-known in the art, as
35 described in Example 3 below. Retroviral vectors are preferred because of their high gene transfer efficiency. The use of the raszip6 vector is particularly preferred for use in the

present invention because this retroviral vector is available in a high viral titer, therefore allowing for a more efficient gene transfer. Although specific examples of vectors useful in practicing the invention are presented herein, it will be
5 apparent to those skilled in the art that many different constructs can be employed, provided that they confer to the transformed (previously immortalized) cell the ability to fully differentiate and preferably also the abilities to grow in semi-solid media and to produce a high level of the normal
10 protein or a mutated gene product.

To be useful in practicing the present invention a vector must meet the following minimum requirements: (1) contain an activated ras gene (or another gene as described above); and (2) be capable of constitutive (i.e. non-regulated)
15 expression in human cells.

In addition, incorporation of a selectable genetic marker in the retroviral vector is preferred for practicing the invention. This permits efficient selection of the EBV-infected, successfully ras-transformed cells. In this selection process, only EBV-ras cells are able to grow while all
20 other cells (e.g., non-transformed EBV-infected B-lymphoblastoid cells) are killed. Selectable genetic markers that can be used in the vectors of the present invention include, by way of non-limiting example, resistance to an antibiotic substance, e.g., neomycin, antibiotic G418 (a variant of neomycin), or
25 hygromycin, or resistance to any other substance that confers a selective advantage to the transfected cells. Indeed, any selectable genetic marker which can be expressed in mammalian cells can be used in practicing the invention. Human lymphoblastoid cells can be made G418 resistant by incorporation
30 of a gene which inhibits the activity of this antibiotic.

Although specific retroviral vectors for use in practicing the present invention are disclosed herein, practice of the invention is not limited to these vectors. Among the
35 other vectors which may be used in practicing the invention are plasmid vectors with the desired properties described above capable of integration into the host cell genome (such plasmids

may be constructed in accordance with techniques that are well-known in the art), or other retroviral vectors (as described in Cepko et al. Cell 37; 1053 (1985)).

The activated human ras gene used in the examples of the present invention was isolated from Harvey Sarcoma virus and is available from the ATCC (Accession No. 41013, American Type Culture Collection, Rockville, MD.) However, any activated ras gene may be used. Three ras genes have already been identified in the mammalian genome. These are designated H-ras-1, K-ras-2, and N-ras (as described in Barbacid, M. Ann. Rev. Biochem. 56: 779-827, 1987). The vectors that are useful in practicing the instant invention should have the ability to produce the mutated gene product discussed above and/or high levels of the normal ras gene product required for the transformation of the EBV-infected B-cells into fully differentiated, tumorigenic B-cells. Activation of the ras gene can be accomplished by (i) the mutation of a specific sequence DNA of the gene, leading to the production of an abnormal protein and/or (ii) by the insertion of an exogenous "enhancer" sequence in the vector DNA adjacent to the ras gene leading to the overproduction of a normal protein. Enhancer sequences have been isolated from the genome of certain tumor viruses (such as Simian Virus 40 (SV40), Banerji et al., Cell 27:299, 1981), and retroviruses (Llucin et al. Cell 33:705, 1983), among others and from the genome of normal mammalian cells (such as the immunoglobulin gene enhancers, as described in Church et al., Nature 313:798, 1985). These sequences have been found to increase the expression of adjacent genes, and their presence in the ras vectors of the present invention leads to deregulated expression. The presence of glycine at position 12 of the ras protein appears to be necessary for the regulated expression of the ras protein. Substitution of Gly¹² by any other amino acid residue (with the exception of proline) results in the oncogenic activation of these molecules. In addition, mutations at codon 13, 59 or 61 (and others) will also result in oncogenic activation (as described in Barbacid, M., Ann. Rev. Biochem. 56: 779-827, 1987). The deregulated

and/or mutated ras gene is termed "activated". Any method suitable for the activation of the human ras gene can be used in practicing the methods of the present invention.

The present invention is further described below in specific examples which are intended to illustrate the invention without limiting its scope.

EXAMPLE 1: ISOLATION OF B-CELLS

The method below has been used for the initial B-cell selection from blood or appropriate blood fractions.

Blood obtained from healthy males and females was placed on a gradient medium for separating lymphocytes (Pharmacia, Piscataway, NJ). Monocytes were removed from other mononuclear cells by two cycles of incubation at 37°C in plastic 150cm² tissue culture flasks. The mononuclear fraction was incubated on ice with sheep red blood cells (SRBC) treated with AET (2-aminoethylisothioronium bromide hydrobromide) (Sigma, St. Louis, MO) to allow for rosette formation. Non-erythrocyte rosette-forming cells (i.e. non-T-cells) were recovered after application of the whole SRBC mononuclear fraction to a lymphocyte-separating medium gradient. The nonadherent, non-rosetting fraction was constituted of at least 50% B-cells, less than 1% monocytes and variable amounts of other lymphocytes.

EXAMPLE 2: EBV INFECTION OF CB33 CELLS

EBV was obtained from culture fluids of B95-8 marmoset lymphoma cells (ATCC No. CRL 1612) incubated in the presence of 1.62x10⁻⁸M 4-phorbol-12 beta-myristate-13-alpha-acetate (TPA, Sigma Fine Chemical Company, St. Louis, MO). The virus preparation had a titer of 5x10⁵ transforming units per ml, one unit being the minimum amount of virus-transforming 10⁴ purified human B-cells. Lymphocytes, at 1 x 10⁶ per ml were exposed to the EBV-containing medium from B85-9 cells, at a multiplicity of infection of 1 transforming unit per cell.

The EBV-infected cells were then cultured for 3-4 weeks in culture medium (RPMI 1640, GIBCO, Grand Island, New

York) continuing 10% fetal calf serum to allow the virus to immortalize these cells.

EXAMPLE 3: CONSTRUCTION OF THE VECTORS
OF THE PRESENT INVENTION

5 The retroviral vectors used in the present invention, SVNras and raszip6, were constructed as follows.

SVNras (described in Souyri et al., Virology 158: 69-78, 1987) was derived from the vector SVX (constructed as described in Capeko et al., Cell 37: 1053-1062, 1984). The
10 SVNras vector consists of the following elements between the long terminal repeats (LTR) of Maloney murine leukemia virus (the sequence of which is described in Hoffmann et al., J. Virol. 44: 144-153, 1982) : the region necessary for viral packaging, the 5' and 3' splicing signals, a DNA sequence
15 coding for neomycin resistance, origins of replication of SV40 virus and the plasmid pBR322 and an activated N-ras gene. The activated N-ras gene was inserted into a unique BamH1 site in SVX in place of missing retroviral gag-pol sequences.

Raszip6 was constructed by inserting the viral H-ras
20 gene (map positions 4,000 to 4,710, Dhar et al., Science 217: 934-937) into the BamH1 site of SVX (Capko et al., supra). The biological properties of raszip6 have been described (Dotto et al., Nature 318: 472-475, 1985).

25 EXAMPLE 4: BIOLOGICAL EFFECTS OF ACTIVATED RAS GENES

In the example presented below the biological effects of activated H-ras and N-ras oncogenes in the same target cells were examined. These oncogenes induced malignant transformation in LCL and, in addition, lead to dramatic phenotypic
30 changes involving terminal differentiation of lymphoblasts into plasma cells.

An activated H-ras allele derived from Harvey Sarcoma Virus (as described in Dhar, R. et al., Science 817:934, 1982), or a human N-ras allele, activated by a mutation at codon 12
35 (as described in Souyri et al., Virology 158:69, 1987), were introduced into LCL derived from normal cord blood (CB33 line) or from adult peripheral blood (UH3 line) by use of amphotropic

retroviral vectors containing the G418-resistance (neo) gene as a selectable marker (see above and Figure 1). A vector (pKneo) containing only the G418 resistance gene was used as a control. After infection, cells were selected in bulk for antibiotic resistance or, in order to ensure the selection of independently infected clones, were plated in limiting dilution followed by antibiotic selection of individual clones. Using either protocol, cell lines were established 2-3 weeks after infection and the presence of clonally distinct viral integration sites was confirmed by Southern blot analysis (not shown).

The expression of retrovirus-encoded genes in infected LCL was examined. The results are shown in Figure 1. RNA was extracted from CB33 cells (Lanes 1), pKneo-infected CB33 cells (Lanes 2), raszip6-infected CB33 cells (Lanes 3), and SVNras infected CB33 cells (Lane 4) purified by the well-known guanidine isothiocyanate method, electrophoresed in 0.9% agarose-2.2 M formaldehyde gels, transferred to nitrocellulose filters, and hybridized with the indicated probes. Schematic representation of the retroviral vectors probes used and expected hybridizing transcripts are also shown in Figure 1. Northern blot hybridization analysis showed the presence of viral ras genes within the genomic-size viral transcripts (Figure 1).

Evidence of phenotypic changes in all cell populations carrying either H- or N-ras oncogenes was immediately manifested as increased cellular volume and increased tendency to adhere to plastic. Morphological examination by light microscopy of cells prepared by routine Giemsa cytochemical staining, well-known in the art, revealed that both parental and control infected CB33 and UH3 cells retained the typical morphology of EBV-immortalized lymphoblastoid cells (small cell volume, high nucleus-to-cytoplasm ratio, multiple prominent nucleoli). In contrast, a significant fraction (>80%) of cells carrying ras oncogenes showed morphological evidence for plasma cell differentiation including an increase in cytoplasm, eccentric placement of the nucleus with the appearance of a single prominent nucleolus and an increase in the number and

size of cytoplasmic inclusions. The remaining cells displayed a relatively less mature, but still plasmacytoid phenotype (see below and Fig. 4). In Fig. 4, the mature plasmacytoid cells are the large lighter shade cells predominant in Fig. 4b. The
5 less mature cells are the darker, smaller ones predominant in Fig. 4a.

Next, evidence was sought of plasma cell differentiation by analyzing immunoglobulin secretion and the expression of cell surface markers associated with terminal differentiation
10 of B-cells to plasma cells (as described in Foon, K.A. and Todd III, R.F., Blood 68:1, 1986).

Cells were plated in triplicate at 2×10^4 well in a 96-well microtitre plate, supernatants were harvested at 2, 4, and 6 days, and assayed for the presence of IgM by an ELISA
15 assay using alkaline-phosphatase-linked antibody to human IgM. No IgA or IgG secretion was detected in any of the infected cell lines (consistent with the fact that the parent lymphoblastoid cells were not selected for IgG secretion). The results are shown in Fig. 2 (the abscissa is days after
20 plating).

In Fig. 2, diamonds refer to cell lines infected with the pKneo virus (control) and squares refer to cell lines infected with the raszip6 virus. Each curve represents data from cell lines derived from distinct infection events. Solid
25 lines represent data from cell lines derived from infection and selection in bulk. Dashed lines represent data from cell lines which were the product of selection of clones.

In all cell populations carrying ras oncogenes there was a marked increase in the secretion of IgM, up to a maximum
30 of a fifteen-fold increase over control infected cells (Figure 2). This increase in IgM secretion was detectable in all oncogene expressing cells including both bulk and clonally infected cells. These cells produced between 10 micrograms and 100 micrograms of antibody per ml of culture fluid.

35 The cell surface expression of lineage-, differentiation-, and activation-specific antigens was studied using monoclonal antibodies in indirect immuno-fluorescence and flow

cytometric analysis. The results are shown in Fig. 3.

In Fig. 3, pKneo-infected (dotted lines, neo) and raszip6-infected (solid lines, ras) CB33 LCL were labelled by indirect immunofluorescence and analyzed by cytofluorometry using the panel of monoclonal antibodies (MoAbs) described in Gotch, F. in Leukocyte Typing III: White Cell Differentiation Antigens, A.J. McMichael, Oxford Press, Oxford, 1987. Representative data were obtained using MoAb MOPC-21 (an isotype-identical negative control, panel a), MoAb TS-1-22 (used as a control with specificity for an antigen, LFA-1 [CD11a], whose expression is not changed, panel b), MoAb PCA-1 (panel c), and MoAb OKT10 (panel d). Analogous results were obtained when analyzing LCL expressing N-ras oncogenes.

Among many markers studied, the most significant and consistent changes were noted in the expression of the OKT10 (CD38) and PCA-1 antigens as manifested by both an increase in the percentage of antibody-reactive cells and increase of the antigen density in LCL expressing either H- or N-ras oncogenes (Figure 3). Expression of both of these antigens is known to increase with plasma cell differentiation.

Ras oncogene expressing cells were then analyzed for growth properties associated with neoplastic transformation. First the ability of these cells to form colonies in soft agar was assayed. The results are shown in Table 1 below.

25

TABLE 1

IN VITRO CLONING EFFICIENCY AND IN VIVO TUMORIGENICITY
OF LCL INFECTED WITH RETROVIRAL CONSTRUCTS

5	<u>CELL LINE</u>	<u>CLONING EFFICIENCY</u>	<u>TUMORIGENICITY</u> <u>tumors/injection</u> <u>latency</u>	
10	HL (P3HR1)* CB-33pHEBOSVmyc2,3*	24% 2.20%	4/4 4/6	2-3 wks. 3-wks.
15	CB33 CB33 neo CB Hras II ^e CB Hras III ^e CB33 Hras IV.1 [#] CB33 Hras IV.2 [#] CB33 Hras I ^e	NA 0 0.31% 0.28% 0.35% 0.25% 0.22%	0/12 0/12 6/6 5/6 6/6 5/6 NT	NA NA 2-3 wks. 2-3 wks. 2-3 wks. 2-3 wks. 2-3 wks.
20	UH3 UH3 neo UH3 Hras I ^e UH3 Hras II ^e UH3 Nras I ^e	0 0 0.07% 0.09% 0.10%	0/6 0/6 5/6 4/6 4/6	NA NA 2-3 wks. 2-3 wks. 2-3 wks.

NT = not tested NA = not applicable

- 30 (x): Burkitt Lymphoma cell line used as a positive control.
 (*) : CB33 LCL transformed by a c-myc oncogene.
 35 (e) : LCL derived from infection and selection in bulk.
 (#) : LCL clones derived from selection in limiting dilution.

40 As seen in Table 1 above, the expression of both H- and N-ras oncogenes appeared to confer a modest, yet consistently detectable clonogenic capability to both CB33 and UH3 LCL under conditions where no colonies were formed by parental or control infected lines. As a second assay for malignant phenotype, the
 45 ability of LCL expressing ras oncogenes and control LCL to form tumors in vivo when injected subcutaneously into a thymic nude mice was tested.

LCL expressing the mutated ras genes were tumorigenic, with subcutaneous tumors appearing 2-3 weeks after injection
 50 (Table 1). These results indicate that ras oncogenes can

confer a rather weak, yet clearly and consistently identifiable transformed phenotype to LCL.

The relationship between proliferation and terminal differentiation in the LCL containing ras oncogenes was then investigated. Two scenarios could be envisioned. First, ras oncogenes could stimulate uncontrolled proliferation associated with stochastic (i.e. random) entrance into a terminal differentiation pathway, resulting in a heterogeneous population of cells including both self-renewing and terminally differentiating proliferatively quiescent subsets. Alternatively, ras oncogene expression could confer proliferative capacity to terminally differentiated cells, resulting in a phenotypically homogeneous population composed of mature, proliferating elements. To discriminate between these two possibilities DNA replication was studied at the single cell level by autoradiographic determination of [^3H]-thymidine uptake. The results are shown in Fig. 4. In Fig. 4, [^3H]-thymidine (1 $\mu\text{C}/\text{ml}$), was added to the growth medium of pKneo-infected (Panel a) and raszip6-infected (panel b) UH3 LCL which were then harvested at 24 hours and transferred to glass slides by cytocentrifugation. Slides were coated with NTB-2 emulsion (Eastman Kodak, Rochester, NY), allowed to expose for 12 days at 4°C, developed, counterstained with Giemsa reagent and assessed for thymidine incorporation. Counting of 200 cells from this experiment showed 61% positive (5 granules/nucleus) cells in pKneo-infected UH3 LCL and 22% positive cells in raszip6-infected UH3 LCL. Analogous experiments performed in CB33 LCL showed 60% and 39% positive cells for pKneo-infected and raszip6-infected LCL respectively.

As shown in Figure 4, cells expressing the ras oncogene displayed an heterogeneous pattern, with thymidine incorporation limited to the smaller, more immature elements and virtually no evidence of DNA replication in the more mature larger elements. While these findings appear to correspond to the first scenario described above, the possibility remained open that the observed heterogeneity was due to clonal variations of cells expressing different levels of ras oncogene. To

directly address this issue, clonogenic cells, namely cells recovered from colonies in semi-solid medium (Table 1 above), were tested to determine whether they were restricted to self-renewal or whether they were also able to generate differentiated progeny. Upon replating in semi-solid medium, these cells did not show any increased clonogenic ability while they rapidly generated mature progeny when grown in liquid culture (not shown). Taken together, these results indicate that ras oncogene expression in LCL stimulated both self-renewal and stochastically determined entrance into a pathway leading to terminally differentiated, quiescent plasma cells.

The results presented above indicate that ras oncogenes can both stimulate sustained growth by cooperating with EBV in transforming LCL and trigger terminal differentiation which is normally blocked in EBV-infected B-cells. Differentiation appears to represent a specific effect of ras oncogene expression rather than a consequence of increased proliferation since expression of c-myc oncogenes in LCL caused analogous alterations of growth, yet no differentiation was observed (not shown).

**EXAMPLE 5: SCREENING FOR SPECIFIC B-CELLS USING
FLUORESCENCE ACTIVATED CELL SORTING (FACS)**

B-cells isolated as described in Example 1 above may be screened for their specificities as described in Casali, P. et al. (op. cit.). Approximately 1×10^6 B-cells will be incubated for 35 minutes in ice-chilled sterile Hanks balanced salt solution without Ca^{2+} or Mg^{2+} and without phenol red containing 1% bovine serum albumin (BSA-HBSS) and appropriate amounts of biotinylated antigen. Typically, 1 mg/ml antigen will be incubated in 0.1M sodium bicarbonate (pH 8.8) and 10% dimethylsulfoxide (DMSO) in the presence of 1 nanogram of d-biotin-N-hydroxysuccinimide ester for 2 hours at room temperature. The cells may be washed with cold BSA-HBSS and then allowed to react with FITC (fluorescein isothiocyanate) avidin (FITC-avidin) ($1.56 \times 10^{-7}\text{M}$) in cold BSA-HBSS for 45 minutes. A small sample of B-cells (10^6) will be simultaneously incubated with

BSA-HBSS devoid of biotinylated antigen and allowed to react with FITC-avidin under similar conditions. After further washing with cold BSA-HBSS, cells from both samples will be resuspended at a density of 10^6 cells per ml in the same medium and at different times applied to a Becton and Dickinson Model 440 FCS with a 488 Argon laser (Becton and Dickinson, Mountain View, CA). Cells which fluoresce in the presence of biotinylated antigen and FITC - avidin are identified and isolated.

10 EXAMPLE 6: USE OF RAS TRANSFORMED, FULLY
DIFFERENTIATED LCL FOR FUSION PARTNERS

Normal human B-cells will be isolated as in Example 1 above, immortalized with EBV as in Example 2 above and transformed with a retroviral vector having an activated ras gene as in Example 4. Successful transformants will be selected by their resistance to G418. Fully differentiated, G418 resistant transformants will be isolated as in Example 4 above.

The fully differentiated, ras-transformed LCL will be selected for growth in appropriate selective media (e.g. containing 6-thioguanosine). LCL that are resistant to growth in this media can be selected for growth in HAT medium because they lack a functional gene for HGPRT.

IgG secreting normal human B-cells, secreting antibodies directed against a specific antigen (e.g. HIV gp41), will be isolated as described in Example 5 above from an HIV seropositive patient. These B-cells will be fused with the mutagenized, immortalized fully differentiated ras-transformed LCL described above using techniques well-known in the art. The HAT resistant (HGPRT minus) cells will be used as fusion partners as described below.

The fusions will be preferably performed in the presence of 50% (w/v) propylene glycol (m.w. 1500, Sigma Chemical, St. Louis, MO). After fusion, the cells will be resuspended in culture medium supplemented with 10% fetal bovine serum and plated overnight in 6 well tissue culture plates. The next day, cells are washed once and plated into 96 well flat bottomed microplates.

Successful fusions will be screened for resistance to G418 and growth in HAT medium. Hybridoma secreting IgG directed against HIV gp41 will be identified and isolated as in Example 5 above.

- 5 The present invention has been illustrated in the foregoing examples. As those skilled in the art will appreciate, however, the present invention is not limited to these specific examples, but is receptive of many additions, deletions and substitutions without departure from the spirit
- 10 of the invention and/or the scope of the following claims.

WHAT IS CLAIMED IS:

- 1 1. A method for preparing human cells that can
2 express monoclonal antibodies and grow in vitro, which com-
3 prises
4 immortalizing human B-cells that express an-
5 tibodies of a desired specificity,
6 transforming said immortalized human B-cells with
7 a vector containing a gene conferring on said cells the ability
8 to differentiate, and
9 selecting immortalized transformants secreting
10 said antibody.
- 1 2. The method of claim 1 wherein said cells are
2 immortalized by infection with Epstein-Barr virus.
- 1 3. The method of claim 1 wherein said gene also
2 confers on said cells the ability to grow on semi-solid media
3 or in animals and enhances the antibody-producing ability of
4 said cells.
- 1 4. The method of claim 3 wherein said gene is an
2 activated ras gene.
- 1 5. The method of claim 1 which comprises transforming
2 said human cells with an effective amount for transformation of
3 said vector.
- 1 6. The method of claim 4 wherein said selecting step
2 comprises selecting for Epstein-Barr Virus infected human B-
3 cells expressing said ras vector.
- 1 7. The method of claim 1 wherein said vector com-
2 prises a retroviral vector.
- 1 8. The method of claim 7 wherein said retroviral
2 vector is a member selected from the group consisting of SVNras
3 and raszip6.

1 9. A method for obtaining transformed human B-cells
2 comprising
3 immortalizing human B-lymphocytes,
4 transforming said immortalized B-lymphocytes with
5 a vector containing a gene which confers on said cells the
6 ability to differentiate, and
7 recovering immortalized differentiated transfor-
8 mants.

1 10. The method of claim 9 comprising immortalizing
2 said cells by infecting them with Epstein-Barr virus.

1 11. The method of claim 9 wherein said gene also
2 confers on said cells the ability to grow on semi-solid media
3 or in animals.

1 12. A transformed human cell comprising a human B-
2 lymphocyte infected with Epstein Barr virus, said cell contain-
3 ing DNA segments coding for a selectable genetic marker, and an
4 activated ras gene in the proper orientation and correct
5 reading frame.

1 13. The transformed human cell of claim 12 wherein
2 said human ras gene is mutated at codon 12.

1 14. The cell of claim 13 secreting human monoclonal
2 antibodies.

1 15. A transformed human cell comprising a human B-cell
2 infected with Epstein Barr virus and containing an activated
3 ras gene.

1 16. A method for producing human monoclonal antibodies
2 which comprises,
3 immortalizing a human B-cell,
4 transforming said immortalized B-cell to incor-

5 porate in said cell a gene that confers on said cell the
6 ability to differentiate,
7 fusing said transformant with a B-cell producing
8 antibody with a predetermined specificity, and thereby produc-
9 ing a hybrid cell having the ability to produce said antibody;
10 culturing said hybrid cell under antibody-produc-
11 ing conditions, and
12 recovering said antibody.

1 17. The method of claim 16 comprising immortalizing
2 said cells by infecting them with Epstein-Barr virus.

1 18. The method of claim 16 wherein said gene also
2 confers on said cell the ability to grow on semi-solid media
3 and in animals.

1 19. The method of claim 18 wherein said gene is an
2 activated ras oncogene.

3 20. A human monoclonal antibody producing cell
4 comprising the fusion product of an Epstein-Barr virus infected
5 ras-transformed B-cell and a human antibody-producing B-cell or
6 the progeny of such fusion product.

1 21. A method for making differentiated human B-cells
2 comprising:
3 transforming an immortalized human B-cell to
4 incorporate in said B-cell a gene which confers on said cell
5 the ability to differentiate; and
6 recovering a differentiated, immortalized B-cell.

7 22. The method of claim 21 wherein said B-cell is
8 immortalized by infection with Epstein-Barr virus.



1 23. The method of claim 21 wherein said gene also
2 confers on said cell the ability to grow on semi-solid media
3 and in animals.

1 24. The method of claim 21 wherein said gene is an
2 activated ras oncogene.

1 25. The method of claim 21 wherein said differentiated
2 immortalized B-cell secretes human monoclonal antibodies.


1/3

FIG. 4



2/3

FIG. 2



SUBSTITUTE SHEET

2/3

FIG. 3b




FIG. 3d




FIG. 3a





FIG. 3c



SUBSTITUTE SHEET

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) *		
According to International Patent Classification (IPC) or to both National Classification and IPC IPC(5): C12N 5/00, 5/06, 5/08, 5/22; C07K 15/04 U.S.CL: 435/69.1, 70.21, 240.21, 240.27;		
II. FIELDS SEARCHED		
Minimum Documentation Searched *		
Classification System	Classification Symbols	
U.S.	435/69.1, 70.21, 240.21, 240.27	
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched *		
Automated Patent System and DIALOG Databases. Search date: 2 April 1990.		
III. DOCUMENTS CONSIDERED TO BE RELEVANT *		
Category *	Citation of Document, ** with indication, where appropriate, of the relevant passages **	Relevant to Claim No. **
L, Y	US, A 4,804,627 (HAMMERLING) 14 FEB 1989. See columns 1 and 2 and abstract. (Filed 1985).	1-25
Y	US, A 4,652,522 (KENNETT). 24 MAR 1987. See columns 3 and 4.	1-25
Y	GODING, <u>Monoclonal Antibodies: Principles and Practice</u> . 1986. Academic Press, New York. See pages 1-3 and 34.	1-25
<p>* Special categories of cited documents: **</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&" document member of the same patent family</p>		
IV. CERTIFICATION		
Date of the Actual Completion of the International Search 4 April 1990		Date of Mailing of this International Search Report 17 APR 1990
International Searching Authority ISA/US		Signature of Authorized Officer Thomas M. Cunningham, Ph.D.

Form PCT/ISA/210 (second sheet) (Rev. 11-87)

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☒ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.